TickerFacts.

Company research / NEO

NeoGenomics Inc (NEO)

Build a valuation ↗↓ Download CSV

SEC name NEOGENOMICS INC · CIK 0001077183 · Nasdaq · Services-Testing Laboratories

  • Sector Services
  • Incorporated NV
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, NeoGenomics Inc reported revenue of $727.33M. Revenue grew 10.1% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $766.29M.

Key ratios (year ended 2025-12-31)

43.2%
Gross margin
-15.9%
Operating margin
-14.9%
Net margin
-12.9%
Return on year-end equity
10.1%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-05

Headquarters locality: Fort Myers · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$766.29M$727.33M$660.57M$591.64M$509.73M$484.33M$444.45M$408.83M$276.74M$240.25M$231.81M
Cost of Revenue$429.76M$413.04M$370.47M$347.04M$321.83M$297.27M$258.56M$211.99M$149.48M$138.29M$133.70M
Gross Profit$336.53M$314.29M$290.10M$244.60M$187.90M$187.06M$185.89M$196.84M$127.27M$101.96M$98.10M
R&D Expense$38.17M$37.08M$31.16M$27.31M$30.33M$21.87M$8.23M$8.49M$3.00M$3.64M$4.65M
Operating Income-$68.44M-$115.88M-$92.11M-$107.74M-$157.62M-$118.75M-$13.99M$13.01M$10.04M$2.90M$2.15M
Depreciation & Amortizationn/an/an/an/an/an/a$25.90M$20.35M$15.80M$15.60M$15.94M
EBITDAn/an/an/an/an/an/a$11.91M$33.35M$25.84M$18.50M$18.09M
Net Income-$51.88M-$108.03M-$78.73M-$87.97M-$144.25M-$8.35M$4.17M$8.01M$2.64M-$396.0K-$6.14M
Total Assets$1.35B$1.36B$1.64B$1.68B$1.74B$1.87B$988.33M$709.51M$505.01M$344.45M$337.12M
Total Liabilities$566.51M$523.27M$735.70M$739.69M$742.01M$761.50M$294.04M$202.10M$184.57M$139.88M$150.52M
Long-Term Debtn/a$341.86M$541.11M$538.20Mn/an/an/an/a$101.75M$96.65M$97.90M
Shareholders' Equity$785.73M$836.56M$902.34M$941.54M$998.02M$1.11B$694.29M$507.41M$320.44M$171.96M$162.32M
Cash & Equivalents$145.54M$159.62M$367.01M$342.49M$263.18M$316.83M$228.71M$173.02M$9.81M$12.82M$12.53M
Operating Cash Flow$22.05M$5.23M$7.02M-$1.95M-$65.99M-$26.72M$1.46M$23.37M$44.79M$18.04M$21.48M
Capital Expenditures$29.40M$27.01M$41.06M$28.75M$30.89M$64.14M$29.10M$20.03M$14.31M$13.69M$7.54M
Free Cash Flow-$7.36M-$21.78M-$34.04M-$30.70M-$96.88M-$90.86M-$27.64M$3.34M$30.48M$4.35M$13.94M
Shares Outstanding127.92M128.15M128.15M127.37M126.91M124.11M112.08M104.78M94.47M80.46M78.57M
Weighted Average Diluted Sharesn/a128.10M126.66M125.50M124.22M119.96M111.79M103.61M91.57M79.43M77.54M

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView